featured
Long-Term Follow-Up Supports the Curative Potential of Axicabtagene Ciloleucel in Patients With Refractory LBCL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
Blood 2023 Feb 23;[EPub Ahead of Print], SS Neelapu, CA Jacobson, A Ghobadi, DB Miklos, LJ Lekakis, OO Oluwole, Y Lin, I Braunschweig, BT Hill, JM Timmerman, A Deol, PM Reagan, PJ Stiff, IW Flinn, U Farooq, A Goy, P McSweeney, J Munoz, T Siddiqi, JC Chavez, AF Herrera, NL Bartlett, AA Bot, RR Shen, J Dong, K Singh, H Miao, JJ Kim, Y Zheng, FL LockeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.